# Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030)

> **NCT04515641** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 12 (actual)

## Conditions studied

- Human Immunodeficiency Virus (HIV) Infection

## Interventions

- **DRUG:** Islatravir

## Key facts

- **NCT ID:** NCT04515641
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-05
- **Primary completion:** 2021-09-13
- **Final completion:** 2021-09-13
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04515641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04515641, "Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04515641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*